

LUNG CANCER RESEARCH FOUNDATION
FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2021 AND 2020

**LUNG CANCER RESEARCH FOUNDATION
FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020**

Table of Contents

	<u>Page</u>
Independent Auditor's Report	1 - 2
Financial Statements	
Statements of financial position	3
Statements of activities	4 - 5
Statements of functional expenses	6 - 7
Statements of cash flows	8
Notes to financial statements	9 - 19

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors
Lung Cancer Research Foundation

Opinion

We have audited the accompanying financial statements of Lung Cancer Research Foundation (a nonprofit organization), which comprise the statements of financial position as of December 31, 2021 and 2020, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Lung Cancer Research Foundation as of December 31, 2021 and 2020, and the changes in net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Lung Cancer Research Foundation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Lung Cancer Research Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Lung Cancer Research Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Lung Cancer Research Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.



CERTIFIED PUBLIC ACCOUNTANTS

Braintree, Massachusetts
July 27, 2022

“Citrin Cooperman” is the brand under which Citrin Cooperman & Company, LLP, a licensed independent CPA firm, and Citrin Cooperman Advisors LLC serve clients’ business needs. The two firms operate as separate legal entities in an alternative practice structure. Citrin Cooperman is an independent member of Moore North America, which is itself a regional member of Moore Global Network Limited (MGNL).

**LUNG CANCER RESEARCH FOUNDATION
STATEMENTS OF FINANCIAL POSITION
DECEMBER 31, 2021 AND 2020**

	<u>2021</u>	<u>2020</u>
<u>ASSETS</u>		
Cash and cash equivalents	\$ 4,973,039	\$ 3,910,801
Contributions receivable, net	595,226	551,477
Prepaid expenses	143,915	28,801
Property and equipment, net	22,415	79,879
Security deposits	<u>3,500</u>	<u>11,000</u>
TOTAL ASSETS	\$ <u>5,738,095</u>	\$ <u>4,581,958</u>
<u>LIABILITIES AND NET ASSETS</u>		
Liabilities:		
Accounts payable and accrued expenses	\$ 341,683	\$ 330,585
Grants payable	1,527,047	1,164,139
Refundable advances	<u>361,367</u>	<u>393,000</u>
Total liabilities	<u>2,230,097</u>	<u>1,887,724</u>
Commitments and contingencies (Notes 4, 8, 11 and 15)		
Net assets:		
Without donor restrictions	2,209,943	2,607,323
With donor restrictions	<u>1,298,055</u>	<u>86,911</u>
Total net assets	<u>3,507,998</u>	<u>2,694,234</u>
TOTAL LIABILITIES AND NET ASSETS	\$ <u>5,738,095</u>	\$ <u>4,581,958</u>

See accompanying notes to financial statements.

**LUNG CANCER RESEARCH FOUNDATION
STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED DECEMBER 31, 2021**

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>
Public support and revenue:			
Contributions and grants	\$ 1,812,475	\$ 2,875,591	\$ 4,688,066
Contributions received under fiscal sponsorship	-	341,382	341,382
Revenue from special events:			
Gross receipts	\$ 1,688,000		
Less: direct costs	<u>322,812</u>		
Revenue from special events, net	1,188,688	176,500	1,365,188
Government grant	390,832	-	390,832
Investment income	1,402	-	1,402
Net assets released from restrictions	<u>2,182,329</u>	<u>(2,182,329)</u>	<u>-</u>
Total public support and revenue and net assets released from restrictions	<u>5,575,726</u>	<u>1,211,144</u>	<u>6,786,870</u>
Expenses:			
Program services	<u>5,103,958</u>	<u>-</u>	<u>5,103,958</u>
Supporting services:			
Management and general	320,481	-	320,481
Fundraising	<u>548,667</u>	<u>-</u>	<u>548,667</u>
Total supporting services	<u>869,148</u>	<u>-</u>	<u>869,148</u>
Total expenses	<u>5,973,106</u>	<u>-</u>	<u>5,973,106</u>
Changes in net assets	(397,380)	1,211,144	813,764
Net assets - beginning of year	<u>2,607,323</u>	<u>86,911</u>	<u>2,694,234</u>
NET ASSETS - END OF YEAR	<u>\$ 2,209,943</u>	<u>\$ 1,298,055</u>	<u>\$ 3,507,998</u>

See accompanying notes to financial statements.

**LUNG CANCER RESEARCH FOUNDATION
STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED DECEMBER 31, 2020**

	Without Donor <u>Restrictions</u>	With Donor <u>Restrictions</u>	<u>Total</u>
Public support and revenue:			
Contributions and grants	\$ 1,150,639	\$ 1,701,286	\$ 2,851,925
Revenue from special events:			
Gross receipts	\$ 2,227,149		
Less: direct costs	<u>317,083</u>		
Revenue from special events, net	1,713,566	196,500	1,910,066
Government grant	442,500	-	442,500
Investment income	1,357	-	1,357
Net assets released from restrictions	<u>1,885,875</u>	<u>(1,885,875)</u>	<u>-</u>
Total public support and revenue and net assets released from restrictions	<u>5,193,937</u>	<u>11,911</u>	<u>5,205,848</u>
Expenses:			
Program services	<u>3,878,972</u>	<u>-</u>	<u>3,878,972</u>
Supporting services:			
Management and general	323,913	-	323,913
Fundraising	<u>718,542</u>	<u>-</u>	<u>718,542</u>
Total supporting services	<u>1,042,455</u>	<u>-</u>	<u>1,042,455</u>
Total expenses	<u>4,921,427</u>	<u>-</u>	<u>4,921,427</u>
Changes in net assets	272,510	11,911	284,421
Net assets - beginning of year	<u>2,334,813</u>	<u>75,000</u>	<u>2,409,813</u>
NET ASSETS - END OF YEAR	<u>\$ 2,607,323</u>	<u>\$ 86,911</u>	<u>\$ 2,694,234</u>

See accompanying notes to financial statements.

**LUNG CANCER RESEARCH FOUNDATION
STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED DECEMBER 31, 2021**

	<u>Supporting Services</u>			Direct Benefit to Donors	Total
	<u>Program Services</u>	<u>Management and General</u>	<u>Fundraising</u>		
Salaries and employee benefits	\$ 1,461,199	\$ 234,786	\$ 358,801	\$ -	\$ 2,054,786
Grants	1,748,591	-	-	-	1,748,591
Professional fees	1,085,846	49,899	29,809	-	1,165,554
Rent	65,437	7,980	19,642	-	93,059
Conferences and meetings	1,219	-	-	250,704	251,923
Bad debt	-	-	37,969	-	37,969
Computer	112,122	13,671	33,654	-	159,447
Public relations	445,850	-	-	-	445,850
Office	98,167	6,203	47,652	61,719	213,741
Travel	11,306	595	-	6,612	18,513
Telephone	15,844	1,932	4,756	-	22,532
Postage	17,969	488	4,255	3,777	26,489
Depreciation	<u>40,408</u>	<u>4,927</u>	<u>12,129</u>	<u>-</u>	<u>57,464</u>
	5,103,958	320,481	548,667	322,812	6,295,918
Expenses included with revenues on the statement of activities	<u>-</u>	<u>-</u>	<u>-</u>	<u>(322,812)</u>	<u>(322,812)</u>
TOTAL EXPENSES	<u>\$ 5,103,958</u>	<u>\$ 320,481</u>	<u>\$ 548,667</u>	<u>\$ -</u>	<u>\$ 5,973,106</u>

See accompanying notes to financial statements.

**LUNG CANCER RESEARCH FOUNDATION
STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED DECEMBER 31, 2020**

	<u>Supporting Services</u>			Direct Benefit to Donors	Total
	Program Services	Management and General	Fundraising		
Salaries and employee benefits	\$ 1,830,650	\$ 253,504	\$ 531,288	\$ -	\$ 2,615,442
Grants	1,156,323	-	-	-	1,156,323
Professional fees	178,491	19,688	28,236	-	226,415
Rent	152,415	18,587	45,749	-	216,751
Conferences and meetings	302	-	-	264,714	265,016
Bad debt	-	-	2,791	-	2,791
Computer	116,174	14,167	34,871	-	165,212
Public relations	33,775	-	-	-	33,775
Office	265,416	7,931	47,882	28,561	349,790
Travel	9,132	481	-	13,847	23,460
Telephone	30,826	3,759	9,253	-	43,838
Postage	62,269	528	5,505	9,961	78,263
Depreciation	<u>43,199</u>	<u>5,268</u>	<u>12,967</u>	<u>-</u>	<u>61,434</u>
	3,878,972	323,913	718,542	317,083	5,238,510
Expenses included with revenues on the statement of activities	<u>-</u>	<u>-</u>	<u>-</u>	<u>(317,083)</u>	<u>(317,083)</u>
TOTAL EXPENSES	<u>\$ 3,878,972</u>	<u>\$ 323,913</u>	<u>\$ 718,542</u>	<u>\$ -</u>	<u>\$ 4,921,427</u>

See accompanying notes to financial statements.

**LUNG CANCER RESEARCH FOUNDATION
STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020**

	<u>2021</u>	<u>2020</u>
Cash flows from operating activities:		
Changes in net assets	\$ 813,764	\$ 284,421
Adjustments to reconcile changes in net assets to net cash provided by operating activities:		
Bad debt expense	37,969	2,791
Depreciation	57,464	61,434
Changes in assets and liabilities:		
Contributions receivable, net	(81,718)	(265,468)
Prepaid expenses	(115,114)	(7,071)
Other assets	7,500	196
Accounts payable and accrued expenses	11,098	87,054
Funds held under agency	-	(119,175)
Refundable advances	(31,633)	68,000
Grants payable	<u>362,908</u>	<u>289,692</u>
Net cash provided by operating activities	1,062,238	401,874
Cash used in investing activities:		
Purchase of property and equipment	<u>-</u>	<u>(2,799)</u>
Net increase in cash and cash equivalents	1,062,238	399,075
Cash and cash equivalents - beginning	<u>3,910,801</u>	<u>3,511,726</u>
CASH AND CASH EQUIVALENTS - ENDING	<u>\$ 4,973,039</u>	<u>\$ 3,910,801</u>

See accompanying notes to financial statements.

LUNG CANCER RESEARCH FOUNDATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

NOTE 1. ORGANIZATION AND NATURE OF OPERATIONS

Lung Cancer Research Foundation (the "Foundation"), formed in 2005, is a non-profit organization operating under the laws of the state of New York. The Foundation's mission is to improve and save lives by funding ground-breaking research for the prevention, diagnosis, treatment and cure of lung cancer.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Foundation have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), which require the Foundation to report information regarding its financial position and activities according to the following nets assets classifications:

Net Assets Without Donor Restrictions - Net assets available for use in general operations and not subject to donor (or certain grantor) restrictions.

Net Assets With Donor Restrictions - Net assets subject to stipulations imposed by donors and grantors. Some restrictions are temporary in nature; those restrictions will be met by actions of the Foundation or by the passage of time. Other restrictions are perpetual in nature, where by the donor had stipulated the funds be maintained in perpetuity. The Foundation does not have any net assets restricted by donors in perpetuity at December 31, 2021 and 2020. The Foundation reports contributions restricted by donors as increases in net assets without donor restrictions if the restrictions expire (that is, when a stipulated time restriction ends or purpose restriction is accomplished) in the reporting period in which revenue is recognized. All other donor-restricted contributions are reported as increases in net assets with donor restrictions, depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from restrictions.

Recently Issued but not yet Effective Accounting Pronouncements

Leases - In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-02, *Leases* ("ASU 2016-02"). This update requires all leases with a term greater than 12 months to be recognized on the statement of financial position through a right-of-use asset and a lease liability and disclosure of information pertaining to leasing arrangements. In July 2018, FASB issued ASU No. 2018-10, *Codification Improvements to Topic 842*, and ASU No. 2018-11, *Leases: Targeted Improvements*, which provided narrow amendments to clarify how to apply certain aspects of the new leases standard and options regarding transition. The standard requires either a modified retrospective transition approach with application in all comparative periods presented, or an alternative transition method, which permits the Foundation to use its effective date as the date of initial application without restating the comparative period financial statements and recognizing any cumulative effect adjustment to the opening statement of retained earnings. ASU 2016-02, as amended, is effective for fiscal years beginning after December 15, 2020. In June 2020, FASB issued ASU No. 2020-05, *Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842)* ("ASU 2020-05"). ASU 2020-05 provided for an optional election to defer the effective date for Topic 842 and related amendments for an additional year. Entities may elect to adopt the guidance on the adoption of Topic 842 for annual reporting periods beginning after December 15, 2021. The Foundation has determined

LUNG CANCER RESEARCH FOUNDATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Recently Issued but not yet Effective Accounting Pronouncements (Continued)

to defer Topic 842 and is evaluating the impact this new guidance will have on its financial statements and related disclosures.

In-kind Contributions - In September 2020, FASB issued ASU No. 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets* ("ASU 2020-07"), which will increase the transparency of contributed nonfinancial assets through enhancements to presentation and disclosure. ASU 2020-07 is effective for fiscal years beginning after June 15, 2021, with early adoption permitted. The Foundation is evaluating the effect that ASU 2020-07 will have on its financial statements and related disclosures

Cash and Cash Equivalents

Cash and cash equivalents consist primarily of cash on deposit and a money market fund. The Foundation considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents.

Revenue Recognition

In accordance with Accounting Standards Codification ("ASC") Topic 606, revenue is measured based on the consideration specified in a contract with a customer, and excludes any amounts collected on behalf of third parties. Under Topic 606, the Foundation recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. The majority of the Foundation's services represent a bundle of services that are not capable of being distinct and as such, are treated as a single performance obligation that is satisfied as the services are rendered. The Foundation determines the transaction price based on contractually agreed-upon rates, adjusted for any variable consideration, if any.

Program services, walks, conventions and meetings, and educational programs are offered by the Foundation throughout the course of the year. Revenues from these services are recognized over time as services are rendered. Event revenue is recognized over the period the event takes place.

Revenue is reported as increases in net assets without donor restrictions unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on assets or liabilities are reported as increases or decreases in net assets without donor restrictions unless their use is restricted by explicit donor stipulations or by law. Expirations of net assets with donor restrictions (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from donor restrictions.

Grants and Contributions

Contributions are presented as restricted support if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions.

LUNG CANCER RESEARCH FOUNDATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Grants and Contributions (Continued)

Contributions, including unconditional promises to give, are recognized as revenues in the period the promise is received. Conditional promises to give, that is, those with a measurable performance or other barriers, are not recognized until they become unconditional, that is, at the time when the conditions on which they depend are substantially met.

Refundable Advance

Contributions related to and received in advance of a fundraising event or stipulated contract year are deferred until the actual occurrence of the event or the appropriate fiscal year, at which time the contributions are then recognized as revenue.

Donated Goods and Services

Donated goods and services are recognized as contributions if the services received (a) create or enhance nonfinancial assets or (b) require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation.

Donated legal and media services amounting to \$757,596 and \$54,486 were provided to the Foundation and have been recorded in the accompanying statements of activities as "Grants" and as "Professional fees" on the accompanying statements of functional expenses for the years ended December 31, 2021 and 2020, respectively.

In addition, a number of unpaid volunteers have made or have agreed to make significant contributions of their time. The value of such contributions is not reflected in these financial statements since these services do not require specialized skills.

Contributions Receivable

Contributions receivable are stated at the amount management expects to collect from outstanding balances. Management evaluates such receivables and establishes an allowance for doubtful accounts based on a history of write-offs and collections and current credit conditions. At both December 31, 2021 and 2020, the allowance for doubtful accounts amounted to \$10,000.

Agency Transactions

The Foundation collects and holds funds on behalf of an unrelated organization or beneficiary. Expenditures of these funds are made by the Foundation when authorized by the beneficiary. The Foundation reflects the funds collected and held as a liability on the accompanying statements of financial condition. Authorized expenditures of these funds are reflected as a reduction of the liability. The changes in such agency funds are summarized in Note 4.

LUNG CANCER RESEARCH FOUNDATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Property and Equipment

The Foundation follows the policy of capitalizing property and equipment purchases of \$5,000 or more. Property and equipment are recorded at cost, less accumulated depreciation. Major expenditures for property and equipment and those which substantially increase useful lives of assets are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets.

Impairment of Long-Lived Assets

The Foundation's long-lived assets are reviewed for impairment in accordance with the guidance of FASB ASC 360, *Property, Plant, and Equipment*, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reportable at the lower of the carrying amount or fair value, less costs to sell. At December 31, 2021 and 2020, management has determined that no long-lived assets are impaired.

Grants Payable

Grant expense and the related grants payable are recorded upon approval by the board of directors.

Functional Allocation of Expenses

The costs of providing the various programs and supporting services have been summarized on a functional basis in the accompanying statements of functional expenses. Accordingly, certain costs have been allocated among the program and supporting services in reasonable amounts and ratios determined by management.

The expenses that are allocated include the following:

<u>Expense</u>	<u>Method of allocation</u>
Salaries and employee benefits	Time and effort
Rent	Time and effort

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

LUNG CANCER RESEARCH FOUNDATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Income Taxes

The Foundation is organized as a New York State nonprofit corporation and has been recognized by the Internal Revenue Service ("IRS") as exempt from federal income taxes under Internal Revenue Code ("IRC") Section 501(a) as organizations described in IRC Section 501(c)(3). The Foundation is annually required to file a Return of Organization Exempt from Income Tax (Form 990) with the IRS. In addition, the entity is subject to income tax on net income that is derived from business activities that are unrelated to its exempt purposes. The Foundation has determined that it is not subject to unrelated business income tax.

The Foundation recognizes and measures its unrecognized tax benefits in accordance with FASB ASC 740, *Income Taxes*. Under that guidance, the Foundation assesses the likelihood, based on their technical merit, that tax positions will be sustained upon examination based on the facts, circumstances and information available at the end of each period. The measurement of unrecognized tax benefits is adjusted when new information is available, or when an event occurs that requires a change.

Management has evaluated the Foundation's tax positions and believes that the Foundation has taken no uncertain tax positions that would require adjustments to the financial statements.

Subsequent Events

In accordance with FASB ASC 855, *Subsequent Events*, the Foundation has evaluated subsequent events through July 27, 2022, the date on which these financial statements were available to be issued. The Foundation is not aware of any material events that required recognition or additional disclosure in these financial statements.

NOTE 3. LIQUIDITY AND AVAILABILITY

The Foundation receives contributions with and without donor restrictions. Contributions received with donor restrictions are to be used in accordance with the associated purpose and/or time restrictions. Typically, restrictions are released during the year received and combined support with and without donor restrictions have historically represented 100% of annual program funding needs.

The Foundation considers contributions with donor restrictions for use in current programs which are ongoing, major, and central to its annual operations to be available to meet cash needs for general expenditures. General expenditures include management and general expenses, fundraising expenses and grant program expenses expected to be paid in the subsequent year. Annual operations are defined as activities occurring during the Foundation's fiscal year.

The Foundation manages its cash available to meet general expenditures following three guiding principles:

- (1) Operating within a prudent range of financial soundness and stability;
- (2) Maintaining adequate liquid assets to fund near-term operating needs; and
- (3) Maintaining sufficient reserves to provide reasonable assurance that long-term grant commitments that support the mission's fulfillment will continue to be met, ensuring the sustainability of the Foundation.

**LUNG CANCER RESEARCH FOUNDATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020**

NOTE 3. LIQUIDITY AND AVAILABILITY (CONTINUED)

The table below presents financial assets available for general expenditures at December 31, 2021:

Cash and cash equivalents	\$ 4,973,039
Contributions receivable, net	<u>595,226</u>
Total financial assets	5,568,265
Less amounts not available for general obligations within one year:	
Net assets with donor restrictions	<u>1,298,055</u>
Financial assets available to meet cash needs for general expenditures within one year	<u>\$ 4,270,210</u>

The Foundation's board of directors meets annually in October to review and approve grant requests. Due to this timing, the Foundation strives to maintain financial assets available to meet general expenditures at a level that represents eight months of expenses for administrative, general and fundraising expenses plus an amount that represents the next expected payment for semi-annual grant commitments approved by the committee, which typically represents approximately 80% of the expected annual grant cash needs.

NOTE 4. TRANSACTIONS IN FUNDS HELD UNDER AGENCY

The asset account "Cash reserved under agency" and the liability account "Funds held under agency" represent contributions received by the Foundation on behalf of the agency it serves.

The financial effects of transactions related to agency funds are recorded as changes in funds held for agency liability and are not included in the accompanying statements of activities.

The changes in that liability for the years ended December 31, 2021 and 2020, are summarized as follows:

	<u>2021</u>	<u>2020</u>
Contributions	\$ 892,569	\$ 645,457
Deductions:		
Distributions	<u>892,569</u>	<u>764,632</u>
Change in agency funds	-	(119,175)
Balance in agency funds - beginning	<u>-</u>	<u>119,175</u>
Balance in agency funds - ending	<u>\$ -</u>	<u>\$ -</u>

**LUNG CANCER RESEARCH FOUNDATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020**

NOTE 5. FISCAL SPONSORSHIP

On October 26, 2017, the Foundation entered into a fiscal sponsorship agreement with a group of organizations, collectively known as the Lung Cancer Mutation Consortium (the "LCMC"). The LCMC conducts activities that align with the mission and purpose of the Foundation. The terms of each agreement require the Foundation to collect contributions on behalf of the LCMC and report them as contributions on the statements of activities. In consideration of its fiscal sponsorships, the Foundation will receive certain project management fees paid directly from the LCMC contributions, as defined in the agreements. Expenses related to each agreement totaled \$86,021 and are recorded in "Salaries and employee benefits" and "Professional fees" on the accompanying statements of functional expenses.

NOTE 6. CONCENTRATIONS OF CREDIT RISK

Financial instruments that potentially subject the Foundation to concentrations of credit risk consist of cash and cash equivalents. The Foundation places cash with high credit quality financial institutions, which are insured by the Federal Deposit Insurance Corporation up to \$250,000. The Foundation believes it is not exposed to any significant credit risk regarding its cash and cash equivalents.

Approximately 41% of the Foundation's total contributions receivable, net were due from two donors at December 31, 2021. Approximately 36% of the Foundation's total contributions receivable, net were due from one donor at December 31, 2020.

NOTE 7. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at December 31, 2021 and 2020:

	<u>2021</u>	<u>2020</u>
Office furniture and equipment	\$ -	\$ 60,874
Computer equipment and software	203,585	203,585
Leasehold improvements	<u>-</u>	<u>76,063</u>
	203,585	340,522
Less: accumulated depreciation	<u>181,170</u>	<u>260,643</u>
Property and equipment, net	<u>\$ 22,415</u>	<u>\$ 79,879</u>

NOTE 8. CONTRIBUTIONS RECEIVABLE

Contributions receivable are due as follows at December 31, 2021 and 2020:

	<u>2021</u>	<u>2020</u>
Receivable in less than one year	\$ 605,226	\$ 561,477
Less: allowance for doubtful accounts	<u>10,000</u>	<u>10,000</u>
	<u>\$ 595,226</u>	<u>\$ 551,477</u>

**LUNG CANCER RESEARCH FOUNDATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020**

NOTE 9. GRANTS PAYABLE

The Foundation made six grants for approximately \$150,000 (Pilot and Disparities Research Grants) and five grants for approximately \$180,000 (AstraZeneca Research Grants) for the year ending December 31, 2021 and eight grants of approximately \$150,000 each for the year ending December 31, 2020. The grants made by the Foundation are each payable over a two-year period. Grant expense amounting to \$1,748,591 and \$1,156,323 has been recognized in "Program services" in the accompanying statements of activities for the years ended December 31, 2021 and 2020, respectively.

The recipients of these grants are unrelated nonprofit organizations and universities with programs focused on developing early diagnostics and better treatment for lung cancer.

Outstanding grants payable amounting to \$1,527,047 and \$1,164,139 have been included in the statements of financial position as of December 31, 2021 and 2020, respectively.

NOTE 10. CONDITIONAL PROMISES TO GIVE

During the years ended December 31, 2021 and 2020, the Foundation received grants totaling approximately \$3,131,300 (the "2021 Conditional Grants") and \$1,898,000 (the "2020 Conditional Grants") (collectively, the "Conditional Grants"), respectively. The Conditional Grants contain grantor conditions (primarily completion of specifically identified events and milestones) and represent conditional promises to give. As such, they are not recorded as contribution revenue until the conditions are met.

Donations received from donors in advance of the conditions being met amounted to approximately \$361,000 and \$393,000 and are included as "Refundable advances" on the accompanying statements of financial position at December 31, 2021 and 2020, respectively.

NOTE 11. NET ASSETS WITH DONOR RESTRICTIONS

The Foundation's net assets with donor restrictions are available to satisfy the following purposes as of December 31, 2021 and 2020:

	2021	2020
Research	\$ 1,298,055	\$ 74,603
Patient education and outreach	-	12,308
	\$ 1,298,055	\$ 86,911

**LUNG CANCER RESEARCH FOUNDATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020**

NOTE 11. NET ASSETS WITH DONOR RESTRICTIONS (CONTINUED)

During the years ended December 31, 2021 and 2020, net assets were released from donor restrictions by incurring expenses satisfying the purpose restrictions or due to the passage of time as follows.

	<u>2021</u>	<u>2020</u>
Research	\$ 866,021	\$ 900,000
Patient education and outreach	495,000	635,000
Events	176,500	196,500
Marketing, communication and donor development	644,808	40,192
Passage of time	<u>-</u>	<u>114,183</u>
	<u>\$ 2,182,329</u>	<u>\$ 1,885,875</u>

NOTE 12. COMMITMENTS

The Foundation was obligated under operating leases for the rental of office space in New York and Wisconsin. The New York office lease terms at 155 East 55th Street, Suite 6E are on a month-to-month basis through January 31, 2022.

The Foundation signed a new lease for a New York location at 501 Seventh Avenue, Suite 401 on January 7, 2022, that expires February 28, 2025

The Foundation is obligated under a three-year office space lease in Wisconsin that began on February 1, 2019, and expires January 31, 2022.

Future minimum rental payments required under the Wisconsin operating lease at December 31, 2021, are as follows:

<u>Year ending December 31:</u>	<u>Amount</u>
2022	\$ <u>2,293</u>

NOTE 13. 401(k) PLAN

The Foundation sponsors a 401(k) profit-sharing plan (the "Plan") for all eligible employees. Contributions to the Plan are made at the discretion of the board of directors. For the years ended December 31, 2021 and 2020, the Foundation made contributions to the Plan amounting to \$57,008 and \$75,398, respectively, which are included in "Salaries and employee benefits" in the accompanying statements of functional expenses.

NOTE 14. RELATED-PARTY TRANSACTIONS

For the years ended December 31, 2021 and 2020, the Foundation received contributions amounting to \$229,555 and \$262,650, respectively, from individuals who are on the board of directors.

**LUNG CANCER RESEARCH FOUNDATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020**

NOTE 15. JOINT COSTS

For the years ended December 31, 2021 and 2020, the Foundation incurred expenses to conduct activities that had both fundraising appeals as well as mission program components ("Joint activities"). The Joint activities include direct mail campaigns. Such costs are allocated among functional expense categories as follows:

	2021	2020
Program services	\$ 17,800	\$ 18,729
Fundraising	26,701	28,093
	\$ 44,501	\$ 46,822

NOTE 16. PAYCHECK PROTECTION PROGRAM

During April 2020 and January 2021, the Foundation received loan proceeds of \$442,500 and \$390,832 under the Paycheck Protection Program (the "PPP") and the Paycheck Protection Program Second Draw Loans (the "PPP SD"), respectively, (collectively the "PPP Loans"). The PPP Loans, which were established as part of the Coronavirus Aid, Relief and Economic Security Act, provides for loans to qualifying businesses for amounts up to 2.5 times certain average monthly payroll expenses of the qualifying business. The loans and accrued interest, or a portion thereof, may be forgiven after 24 weeks so long as the borrower uses the loan proceeds for eligible purposes including payroll, benefits, rent, mortgage interest and utilities, and maintains its payroll levels. Not more than 40% of the amount forgiven can be attributable to nonpayroll costs.

The PPP loan matures two years from the date of first disbursement of proceeds to the Foundation (the "PPP Loan Date") and accrues interest at a fixed rate of 1%. Payments are deferred for the first ten months and payable in equal consecutive monthly installments of principal and interest commencing upon expiration of the deferral period of the PPP Loan Date.

The PPP SD loan matures five years from the date of first disbursement of proceeds to the Foundation and accrues interest at a fixed rate of 1%. Payments are deferred for the covered period plus 10 months and payable in 50 equal consecutive monthly installments of principal and interest commencing on the 11-month anniversary of the end of the covered period.

The Foundation currently intends to use the proceeds for purposes consistent with the PPP SD, however, there can be no assurances that the Foundation will ultimately meet the conditions for forgiveness of the loan or that management will not take actions that could cause the Foundation to be ineligible for forgiveness of the loan, in whole or in part.

LUNG CANCER RESEARCH FOUNDATION
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

NOTE 16. PAYCHECK PROTECTION PROGRAM (CONTINUED)

U.S. GAAP does not contain authoritative accounting standards for forgivable loans provided by governmental entities. Absent authoritative accounting standards, interpretative guidance issued and commonly applied by financial statement preparers allows for the selection of accounting policies amongst acceptable alternatives. Based on the facts and circumstances, the Foundation has determined it most appropriate to account for the PPP loan proceeds under the conditional contribution model within ASC 958-605. Under the conditional contribution model, the Foundation recognizes the proceeds received as a refundable advance, and subsequently recognizes grant revenue as the conditions are met. Conditions are deemed to be met as the allowable expenses are incurred. The Foundation deemed the conditional contribution model to be the most appropriate accounting policy for this arrangement based on the nature of the PPP loan program

The Foundation recognized \$390,832 and \$442,500 in grant revenue under the PPP loan program during the years ended December 31, 2021 and 2020, which are included in "Government grant" on the accompanying statements of activities.

The Foundation applied for PPP loan forgiveness in the amount of \$390,832 and received approval from the Small Business Association in August 2021. If it is determined that the Foundation was not eligible to receive the PPP loan or that the Foundation has not adequately complied with the rules, regulations and procedures applicable to the SBA's loan program, the Foundation could be subject to penalties and could be required to repay amounts previously forgiven.